An expert panel consisting of dietitians, doctors, nutritional epidemiologists, chefs, and weight loss researchers examined ...

(HealthDay News) — Vaccines to protect against respiratory syncytial virus (RSV) in newborns and older adults are being more ...

Significant reductions seen in birth weight with exposure to certain DMTs, and increase seen in rate of small for gestational age ...

The FDA is expected to decide on treatments for Parkinson disease, PTSD and NF1-associated plexiform neurofibromas, in addition to 2 new vaccines.

(HealthDay News) — Racial and ethnic disparities are seen in the use of obesity management medications, according to a study published online Dec. 17 in the Journal of Racial and Ethnic Health ...

The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.

The Company has been granted Competitive Generic Therapy designation, which allows for 180 days of marketing exclusivity.

Results from the VENTURE trial showed significant reductions in weight and hunger among younger patients treated with ...

Vaccine effectiveness of 52.8% seen for ED visits, 52.3% for noncritical hospitalization, 50.4% for critical hospitalization.

The researchers found that between 1999 and 2022, there were 63,550,429 deaths in the United States, of which 0.06% had cold recorded as an underlying or contributing cause of death. Cold-related ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under Priority Review for avutometinib, in combination with defactinib, for the treatment of adults with ...